Navigation Links
Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call

WEIFANG, Shandong, China, May 13 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the three months ended March 31, 2009 after the close of the stock market on Thursday, May 14, 2009. Management will conduct a conference call on Friday, May 15, 2009 at 8:30 A.M. Eastern Daylight Time to discuss these results. A question and answer session will follow management's presentation.

Ms. Yiru Melody Shi (Chief Financial Officer), and Ms. Michelle Wang (Investor Relations Manager) will be the primary speakers on the call.

A live webcast of the conference call will be available on the Investor Relations page of Shengtai Pharmaceutical's web site at . Please visit the Web site at least 15 minutes early to register for the webcast and download any necessary audio software.

To participate, please call the following numbers ten minutes before the call start time:

               Phone Number + 1 (877) 407-9205 (North America)
               Phone Number + 1 (201) 689-8054 (International)

A replay of the call will be available through Thursday, May 21, 2009, at 11:59 P.M. Eastern Daylight Time. For the replay, please call:

               Phone Number +1 (877) 660-6853 (North America)
               Phone Number +1 (201) 612-7415 (International)
               Account Number: 286
               Conference ID Number: 323305

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China.

Forward-looking Statements

Certain statements made in this news release, may contain forward-looking statements concerning the Company's business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, future increases in market demand, possible increases in our market share and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large-scale implementation of the Company's business plan, the ability to attract new customers, ability to increase our products' applications, cost of raw materials, downturns in the Chinese and world economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

    For more information, please contact:

    Shengtai Pharmaceutical, Inc.
     Ms. Yiru Melody Shi
     Chief Financial Officer

     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
6. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical Expands International Sales Program
9. Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference
10. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
11. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... Ruth Pearson ... brutal lupus flare-up. Unable to walk without assistance and quickly losing hope of recovering ... then a miracle happened. , Pearson was attending a women’s retreat when she experienced ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology: